Talanx AG (0QA8)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 126.85 |
|---|---|
| 52-week range | 97.85 – 128.80 |
| Return, 1 month / 3 months | +5.7% / +11.9% |
| Return, 1 year / 3 years | +20.6% / +141.1% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 22.0% |
| Worst drawdown (1 year) | -14.8% |
| Average daily value traded | 3.30M EUR |
| Dividend yield | 2.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Talanx is a German insurance group based in Hanover. It provides property and casualty insurance, life and health insurance, and reinsurance through brands such as HDI, serving industrial and commercial clients as well as private customers in Germany and other countries. Its industrial insurance arm covers large corporate risks, while its retail operations offer cover to individuals and small businesses. The group also holds a majority stake in the reinsurer Hannover Re.
The shares are listed on the London Exchange in UK under the code 0QA8, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Talanx AG (0QA8) trades on the London Exchange in UK. It last closed at EUR 126.85 on 22 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 284 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.6% and over the last three months it rose 11.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.8% | ||
| From 52-week high | -0.9% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.9% | ||
| 6-month return | 10.3% | ||
| 12-month return, skipping the last month | 14.1% | ||
| Stability (higher is calmer) | 84 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.8% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.30M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.8% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.0% |
|---|---|
| 1 month | +5.7% |
| 3 months | +11.9% |
| 6 months | +10.3% |
| 1 year | +20.6% |
| 3 years | +141.1% |
| 5 years | +277.5% |
Signals
| 50-day / 200-day average | 121.66 / 110.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.55 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 May 2026 | EUR 3.6000 |
| 9 May 2025 | EUR 2.7000 |
| 8 May 2024 | EUR 2.3500 |
| 5 May 2023 | EUR 2.0000 |
| 6 May 2022 | EUR 1.6000 |
| 7 May 2021 | EUR 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.